Z-Fix

Z-Fix

cefixime

Manufacturer:

Rainbow Life Sciences

Distributor:

Zyre Pharma

Marketer:

Ambica
Full Prescribing Info
Contents
Cefixime trihydrate.
Description
Each 5 mL reconstituted suspension contains: Cefixime (as Trihydrate) USP equivalent to Anhydrous Cefixime 100 mg.
Action
Pharmacology: Pharmacokinetics: Only 40 to 50% of an oral dose of Cefixime is absorbed from the gastrointestinal tract, whether taken before or after meals, although the rate of absorption may be decreased in the presence of food. Cefixime is better absorbed from oral suspension than from tablets. Absorption is fairly slow; peak plasma concentrations of 2 to 3 micrograms/mL and 3.7 to 4.6 micrograms/mL have been reported between 2 and 6 hours after single doses of 200 and 400 mg, respectively. The plasma half-life is usually about 3 to 4 hours and may be prolonged when there is renal impairment. About 65% of Cefixime is bound to plasma proteins.
Information on the distribution of Cefixime in body tissues and fluids is limited. It crosses the placenta. Relatively high concentrations may be achieved in bile and urine. About 20% of an oral dose (or 50% of an absorbed dose) is excreted unchanged in the urine within 24 hours. Up to 6% may be eliminated by non renal mechanism; there is no evidence of metabolism but some is probably excreted in the feces from bile. It is not substantially removed by dialysis.
Antimicrobial Action: Cefixime is bactericidal and is stable to hydrolysis by many beta-lactamase. It has a mode of action and spectrum of activity similar to that of the third generation cephalosporin cefotaxime, but some enterobacteriaceae are less susceptible to Cefixime. Haemophilus influenzae, Moraxella catarrhalis (Branhamella catarrhalis) and Neisseria gonorrhoeae are sensitive, including penicillinase-producing strains of the Gram-positive bacteria, Streptococci are sensitive to Cefixime but most strains of Staphylococci, Enterococci and Listeria spp. are not. Enterobacter spp., Pseudomonas aeruginosa, and Bacteroides spp,. are resistant to Cefixime.
Indications/Uses
For the treatment of infections due to sensitive Gram-positive and Gram-negative bacteria.
Dosage/Direction for Use
Children over 6 months: 8 mg/kg daily in 1 to 2 divided doses; or 6 months up to 1 year: 7.5 mL daily.
Children 1 to 4 years: 10 mL daily.
Children 5 to 10 years: 20 mL daily.
The usual course of treatment is 7 days. This may be continued for up to 14 days if required. Or as prescribed by the physician.
Direction for Reconstitution: Shake bottle to loosen the powder. Slowly add boiled and then cooled water up to the mark on the bottle. Shake vigorously. The reconstituted suspension should be stored at temperatures between 2 to 8°C and should be used within 7 days.
Do not freeze.
Shake well before use.
Contraindications
Hypersensitivity to the active substance of to any of the excipients.
Adverse Reactions
The most frequently reported adverse effects of Cefixime are gastrointestinal disturbances, especially diarrhea. Cefixime should be stopped if diarrhea is severe.
Although Cefixime does not have the N-methylthiotetrazote side-chain usually associated with hypoprothrombinemia, increases in prothrombin times have occurred in a few patients.
Drug Interactions
Care should be exercised in patients receiving anticoagulants and Cefixime due to the possibility that Cefixime may increase prothrombin times.
Storage
Store at temperatures not exceeding 30°C.
MIMS Class
ATC Classification
J01DD08 - cefixime ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Presentation/Packing
Powd for oral susp 100 mg/5 mL x 30 mL, 60 mL.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in